Attention! Information is for reference only!
Before taking the course, consult a doctor!
WEB SITE ONLY DIRECTORY. NOT PHARMACY! We do not sell medicines! None!
0 1 2 3 4 5 6 7 8 A B C D E F G H I J K L M N O P Q R S T U V W X Y

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Description of the medicine: Montelukast (Montelukast)

MONTELUKAST (Montelukast).

Sodium salt of 1 - [[[R) -m - [(E) -2- (7-chloro-2-quinolyl) -vinyl] -α- [o- (1-hydroxy-1-methylethyl) phenethyl] benzyl ] Thio] -methyl] cyclopropane acetate.

Synonym: Singular, Singular.

A new bronchodilator drug, similar in effect to zafirlukastu (acolat). Like zafirlukastu, is a blocker of leukotriene receptors (LTS 4 , LTD 4 , LTE 4 ) and has a bronchodilating and anti-inflammatory effect in bronchial asthma and other bronchospastic states.

When ingested quickly and completely absorbed, bioavailability is about 70%, C max -2-3 h; Is biotransformation in the liver, excreted by the kidneys.

The main indications for the use of montelukast are prevention and long-term treatment of bronchial asthma. For relief of asthma attacks, including asthmatic status, the drug is not used.

Assign adults and adolescents (15 years and older) inward in the form of tablets of 0.01 g (10 mg) 1 time per day (evening). Children aged 6-15 years are recommended in the form of chewable tablets to 0,005 grams (5 mg) once a day (in the evening). Children under 5 years of age are not prescribed a drug (due to lack of necessary data).

Montelukast is usually well tolerated. Possible headache, dyspepsia, swelling of the nasal mucosa, cough, increased activity (induction) of liver enzymes.

Contraindicated in pregnancy, breast-feeding, at the age of 6 years.

Treatment Montelukastom, as well as other inhibitors of leukotrienes and in general new drugs, should be conducted under medical supervision. It is necessary to have ready means of rapid relief of bronchospasm in case of their occurrence. Replacing montelukast other drugs (glucocorticosteroids, etc.) should be done gradually. Care must be taken when administering to patients with impaired liver function.

In connection with the potential induction of liver enzymes (cytochrome P-450), it is necessary to consider the possibility of changing the pharmacokinetics (with decreasing activity) of a number of drugs - theophylline, coumarin anticoagulants, terfenadine, etc.

Forms of release: tablets of 0.01 g (10 mg); Chewable tablets of 0.005 g (5 mg) (N. 7, 14, 28).

Storage: List B, at temperatures from +15 to +30 ° C in a dry, dark place.